Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online

BACKGROUND: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary harms from treatment. The new 21-gene assay (OncotypeDX,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahn, Beate, Rochau, Ursula, Kurzthaler, Christina, Hubalek, Michael, Miksad, Rebecca, Sroczynski, Gaby, Paulden, Mike, Bundo, Marvin, Stenehjem, David, Brixner, Diana, Krahn, Murray, Siebert, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://www.ncbi.nlm.nih.gov/pubmed/29037213
http://dx.doi.org/10.1186/s12885-017-3603-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644100/
https://www.ncbi.nlm.nih.gov/pubmed/29037213
http://dx.doi.org/10.1186/s12885-017-3603-z

Ejemplares similares